A Case Report on the Dramatic Response of 177Lu-PSMA Therapy for Metastatic Prostate Cancer
Current Medical Imaging, cilt.21, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21
- Basım Tarihi: 2025
- Doi Numarası: 10.2174/0115734056362468250709045212
- Dergi Adı: Current Medical Imaging
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Compendex, EMBASE, MEDLINE
- Anahtar Kelimeler: Prostate-specific membrane antigen, Metastatic castration-resistant prostate cancer, Prostate cancer, Lu-177-PSMA, Radioligand therapy, Theranostics
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (177Lu-PSMA) therapy. Case Presentation: A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving 177Lu-PSMA therapy, the patient’s PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of 177Lu-PSMA therapy, exceptional results were observed. Conclusion: 177Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.